MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:ALMKS • ES0105463006

8.6 EUR
+0.05 (+0.58%)
Last: Feb 2, 2026, 07:00 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ALMKS. ALMKS was compared to 68 industry peers in the Media industry. ALMKS has a bad profitability rating. Also its financial health evaluation is rather negative. ALMKS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • ALMKS had negative earnings in the past year.
  • In the past year ALMKS had a positive cash flow from operations.
  • In the past 5 years ALMKS reported 4 times negative net income.
  • ALMKS had a positive operating cash flow in 4 of the past 5 years.
ALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFALMKS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

1.2 Ratios

  • ALMKS has a worse Return On Assets (-0.99%) than 67.65% of its industry peers.
  • With a Return On Equity value of -6.62%, ALMKS is not doing good in the industry: 67.65% of the companies in the same industry are doing better.
  • ALMKS's Return On Invested Capital of 7.51% is fine compared to the rest of the industry. ALMKS outperforms 69.12% of its industry peers.
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROIC 7.51%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ALMKS.PA Yearly ROA, ROE, ROICALMKS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

  • ALMKS's Operating Margin of 1.86% is in line compared to the rest of the industry. ALMKS outperforms 41.18% of its industry peers.
  • In the last couple of years the Operating Margin of ALMKS has declined.
  • Looking at the Gross Margin, with a value of 20.80%, ALMKS is doing worse than 80.88% of the companies in the same industry.
  • ALMKS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 1.86%
PM (TTM) N/A
GM 20.8%
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
ALMKS.PA Yearly Profit, Operating, Gross MarginsALMKS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 20

More info and screens

2

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ALMKS is still creating some value.
  • ALMKS has more shares outstanding than it did 1 year ago.
  • ALMKS has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for ALMKS has been reduced compared to a year ago.
ALMKS.PA Yearly Shares OutstandingALMKS.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
ALMKS.PA Yearly Total Debt VS Total AssetsALMKS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 1.74, we must say that ALMKS is in the distress zone and has some risk of bankruptcy.
  • ALMKS's Altman-Z score of 1.74 is fine compared to the rest of the industry. ALMKS outperforms 60.29% of its industry peers.
  • ALMKS has a debt to FCF ratio of 1140.00. This is a negative value and a sign of low solvency as ALMKS would need 1140.00 years to pay back of all of its debts.
  • The Debt to FCF ratio of ALMKS (1140.00) is worse than 60.29% of its industry peers.
  • ALMKS has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • ALMKS has a better Debt to Equity ratio (0.46) than 61.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Altman-Z 1.74
ROIC/WACC1.1
WACC6.86%
ALMKS.PA Yearly LT Debt VS Equity VS FCFALMKS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that ALMKS may have some problems paying its short term obligations.
  • ALMKS has a worse Current ratio (0.76) than 70.59% of its industry peers.
  • A Quick Ratio of 0.73 indicates that ALMKS may have some problems paying its short term obligations.
  • ALMKS has a worse Quick ratio (0.73) than 64.71% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.73
ALMKS.PA Yearly Current Assets VS Current LiabilitesALMKS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

  • ALMKS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.58%, which is quite impressive.
  • The Revenue has grown by 16.22% in the past year. This is quite good.
  • Measured over the past years, ALMKS shows a very strong growth in Revenue. The Revenue has been growing by 51.26% on average per year.
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.62% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 22.10% on average over the next years. This is a very strong growth
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ALMKS.PA Yearly Revenue VS EstimatesALMKS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
ALMKS.PA Yearly EPS VS EstimatesALMKS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0.1 0.2 0.3 0.4 0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • ALMKS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • ALMKS is valuated quite expensively with a Price/Forward Earnings ratio of 35.13.
  • ALMKS's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. ALMKS is more expensive than 64.71% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 25.64, ALMKS is valued a bit more expensive.
Industry RankSector Rank
PE N/A
Fwd PE 35.13
ALMKS.PA Price Earnings VS Forward Price EarningsALMKS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ALMKS is valued a bit more expensive than 61.76% of the companies in the same industry.
  • ALMKS's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. ALMKS is more expensive than 60.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF 1544.56
EV/EBITDA 9.36
ALMKS.PA Per share dataALMKS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ALMKS's earnings are expected to grow with 15.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.46%
EPS Next 3Y15.62%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for ALMKS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

MAKING SCIENCE GROUP SA

EPA:ALMKS (2/2/2026, 7:00:00 PM)

8.6

+0.05 (+0.58%)

Chartmill FA Rating
GICS IndustryGroupMedia & Entertainment
GICS IndustryMedia
Earnings (Last)07-31
Earnings (Next)N/A
Inst Owners3.56%
Inst Owner ChangeN/A
Ins Owners61.03%
Ins Owner ChangeN/A
Market Cap77.23M
Revenue(TTM)274.00M
Net Income(TTM)-1.72M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 35.13
P/S 0.28
P/FCF 1544.56
P/OCF 234.02
P/B 2.97
P/tB N/A
EV/EBITDA 9.36
EPS(TTM)-0.2
EYN/A
EPS(NY)0.24
Fwd EY2.85%
FCF(TTM)0.01
FCFY0.06%
OCF(TTM)0.04
OCFY0.43%
SpS30.51
BVpS2.9
TBVpS-4.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.99%
ROE -6.62%
ROCE 10.22%
ROIC 7.51%
ROICexc 13.46%
ROICexgc N/A
OM 1.86%
PM (TTM) N/A
GM 20.8%
FCFM 0.02%
ROA(3y)-2.49%
ROA(5y)-1.44%
ROE(3y)-23.01%
ROE(5y)-9.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-6.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.93%
GM growth 5Y-5%
F-Score6
Asset Turnover1.58
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 1140
Debt/EBITDA 1.03
Cap/Depr 4.29%
Cap/Sales 0.1%
Interest Coverage 1.14
Cash Conversion 2.84%
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.73
Altman-Z 1.74
F-Score6
WACC6.86%
ROIC/WACC1.1
Cap/Depr(3y)13.72%
Cap/Depr(5y)311.76%
Cap/Sales(3y)0.4%
Cap/Sales(5y)7.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-323.33%
EPS Next Y-27.27%
EPS Next 2Y11.46%
EPS Next 3Y15.62%
EPS Next 5YN/A
Revenue 1Y (TTM)16.22%
Revenue growth 3Y35.39%
Revenue growth 5Y51.26%
Sales Q2Q%21.45%
Revenue Next Year33.94%
Revenue Next 2Y25.99%
Revenue Next 3Y22.1%
Revenue Next 5YN/A
EBIT growth 1Y278.77%
EBIT growth 3YN/A
EBIT growth 5Y41.58%
EBIT Next Year200%
EBIT Next 3Y56.86%
EBIT Next 5YN/A
FCF growth 1Y103.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y178.57%
OCF growth 3Y-64.23%
OCF growth 5YN/A

MAKING SCIENCE GROUP SA / ALMKS.PA FAQ

What is the fundamental rating for ALMKS stock?

ChartMill assigns a fundamental rating of 2 / 10 to ALMKS.PA.


Can you provide the valuation status for MAKING SCIENCE GROUP SA?

ChartMill assigns a valuation rating of 0 / 10 to MAKING SCIENCE GROUP SA (ALMKS.PA). This can be considered as Overvalued.


What is the profitability of ALMKS stock?

MAKING SCIENCE GROUP SA (ALMKS.PA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for MAKING SCIENCE GROUP SA?

The Earnings per Share (EPS) of MAKING SCIENCE GROUP SA (ALMKS.PA) is expected to decline by -27.27% in the next year.